[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-355675-105":59,"doc-detail-355675-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","hereditary-cancer-syndromes-with-gynecological-cancer-risk-focus-on-prevention-strategies","Hereditary cancer syndromes with gynecological cancer risk - focus on prevention strategies","","Hereditary cancer syndromes carrying pathogenic variants in BRCA1/2 and mismatch-repair genes substantially increase the lifetime risk of gynecologic malignancies, particularly ovarian, endometrial, and fallopian tube cancers. Given limited screening efficacy, especially for ovarian cancer, the review synthesizes evidence on identification, risk stratification, surveillance, chemoprevention, and prophylactic surgery. It proposes a precision-prevention framework integrating genomic testing, counseling models, and multidisciplinary coordination. Ethical and health-economic considerations and emerging tools such as liquid biopsy need further validation.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":35,"@type":76,"position":81},"https://docshare.wps.com/document/healthcare/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/hereditary-cancer-syndromes-with-gynecological-cancer-risk-focus-on-prevention-strategies/355675/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/hereditary-cancer-syndromes-with-gynecological-cancer-risk-focus-on-prevention-strategies/355675.png","ImageObject",300,407,{"name":92,"@type":93},"Putri","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-09-23","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":14},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why focus on prevention for gynecologic cancers in hereditary cancer syndromes?","Question",{"text":112,"@type":113},"Gynecologic cancers, especially ovarian cancer, are often diagnosed at advanced stages, leading to high morbidity and mortality. With well-characterized lifetime risks and evidence-based risk-reduction options, prevention is a key component of clinical management.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What evidence supports improved identification of carriers in hereditary syndromes?",{"text":117,"@type":113},"The review highlights expanded germline testing, universal mismatch-repair screening, and genomic profiling, which improve carrier identification beyond family-history-based criteria.",{"name":119,"@type":110,"acceptedAnswer":120},"Which prevention strategies are emphasized for genetically predisposed women?",{"text":121,"@type":113},"The strategies include integrated counseling, risk-adapted surveillance, chemoprevention with hormonal and anti-inflammatory agents, and prophylactic surgery such as salpingo-oophorectomy, hysterectomy, or investigational salpingectomy with delayed oophorectomy.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},355675,1790179346,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":34,"category_name":35,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":14,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145},962085571259,"https://ap-avatar.wpscdn.com/davatar_29158cc5080c5b710cf443261637dec0","TYPE Review  \nPUBLISHED 28 April 2026  \nDOI 10.3389/fonc.2026.1811964  \nOPEN ACCESS  \nEDITED BY  \nAnton A. Buzdin,  \nEuropean Organisation for Research and Treatment of Cancer, Belgium  \nREVIEWED BY  \nMaria C. Katapodi,  \nUniversity of Basel, Switzerland Chiara Cassani,  \nUniversity of Pavia, Italy  \n*CORRESPONDENCE  \nValentina Iacobelli  \n valentina. iacobelli@ [guest.policlinicogemelli.it](guest.policlinicogemelli.it)  \nRECEIVED 15 February 2026  \nREVISED 25 March 2026  \nACCEPTED 14 April 2026  \nPUBLISHED 28 April 2026  \nCITATION  \nDuranti S, Iacobelli V, Trozzi R, Camarda F, Panfili A, Fagotti A, Fanfani F, Marchetti C and Nero C (2026)  \nHereditary cancer syndromes with gynecological cancer risk: focus on prevention strategies.  \nFront. Oncol. 16:1811964 .  \ndoi: 10.3389/fonc.2026.1811964  \nCOPYRIGHT  \n© 2026 Duranti, Iacobelli, Trozzi, Camarda, Panfili, Fagotti, Fanfani, Marchetti and Nero. This is an openaccess article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nHereditary cancer syndromes with gynecological cancer risk:  \nfocus on prevention strategies  \nSimona Duranti 1, Valentina Iacobelli 2,3*, Rita Trozzi 2,3, Floriana Camarda 2,3, Arianna Panfili4, Anna Fagotti 2,3, Francesco Fanfani 2,3, Claudia Marchetti 2,3 and Camilla Nero 2,3  \n1Scientific Directorate, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, 2 Unit of Oncological Gynecology, Women’s Children ’s and Public Health Department, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy, 3 Università Cattolica del Sacro Cuore, Rome, Italy, 4 UOC Genetica Medica, Fondazione Policlinico Universitario Agostino Gemelli, IRCCS, Rome, Italy  \nBackground: Hereditary cancer syndromes, including pathogenic variants in BRCA1/2 and mismatch-repair genes, confer a substantial risk of several malignancies, including ovarian, endometrial, and fallopian tube cancers. Given the limited efficacy of current screening strategies, particularly for ovarian cancer, a prevention-focused approach is required. This review synthesizes evidence onidentification, risk stratification, surveillance, chemoprevention, and prophylactic surgery in women with inherited gynecologic cancer susceptibility, proposing a precision-prevention framework.  \nMethods: A structured search of MEDLINE, Embase, and the Cochrane Library was conducted through July 2025 . Original studies, reviews, and guidelines in English were included following independent screening and full-text assessment by two authors.  \nResults: Expanded germline testing, universal mismatch-repair screening, and genomic profiling have improved carrier identification beyond family history– based criteria. Integrated counseling models enhance informed decision-making and access to care. Conventional surveillance tools show limited sensitivity; emerging strategies, including circulating tumor DNA assays and artificial intelligence, require further validation. Hormonal and anti-inflammatory agents demonstrate potential for risk reduction. Prophylactic surgery, including salpingo-oophorectomy, hysterectomy, or investigational salpingectomy with delayed oophorectomy, remains central, requiring multidisciplinary evaluation and attention to fertility, menopausal health, and patient preferences. Ethical and health-economic considerations remain critical in clinical practice and policy development. Further studies are warranted to better elucidate the potential role of liquid biopsy, microbiota, and targeted vaccination strategies.  \nConclusions: Prevention of gynecologic cancers in genetically predisposed women requires an integrated strategy ","cbCaiul93aglCLjP","https://ap.wps.com/l/cbCaiul93aglCLjP","pdf",1516259,14,"English","# Introduction\n# Background\n# Methods\n# Results\n## Identification and risk assessment\n## Surveillance and emerging strategies\n## Risk-reduction interventions\n# Conclusions","[{\"question\":\"Why focus on prevention for gynecologic cancers in hereditary cancer syndromes?\",\"answer\":\"Gynecologic cancers, especially ovarian cancer, are often diagnosed at advanced stages, leading to high morbidity and mortality. With well-characterized lifetime risks and evidence-based risk-reduction options, prevention is a key component of clinical management.\"},{\"question\":\"What evidence supports improved identification of carriers in hereditary syndromes?\",\"answer\":\"The review highlights expanded germline testing, universal mismatch-repair screening, and genomic profiling, which improve carrier identification beyond family-history-based criteria.\"},{\"question\":\"Which prevention strategies are emphasized for genetically predisposed women?\",\"answer\":\"The strategies include integrated counseling, risk-adapted surveillance, chemoprevention with hormonal and anti-inflammatory agents, and prophylactic surgery such as salpingo-oophorectomy, hysterectomy, or investigational salpingectomy with delayed oophorectomy.\"}]","Hereditary cancer syndromes with gynecological cancer risk - focus on prevention strategies | PDF",1790120459,35]